268 related articles for article (PubMed ID: 15948982)
1. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
Brennand S; Sutton VR; Biagi J; Trapani JA; Westerman D; McCormack CJ; Seymour JF; Kennedy G; Prince HM
Br J Dermatol; 2005 Jun; 152(6):1199-205. PubMed ID: 15948982
[TBL] [Abstract][Full Text] [Related]
2. Oral bexarotene in a therapy-resistant Sézary syndrome patient: observations on Sézary cell compartmentalization.
el-Azhary RA; Bouwhuis SA
Int J Dermatol; 2005 Jan; 44(1):25-8. PubMed ID: 15663654
[TBL] [Abstract][Full Text] [Related]
3. Bexarotene therapy for mycosis fungoides and Sézary syndrome.
Abbott RA; Whittaker SJ; Morris SL; Russell-Jones R; Hung T; Bashir SJ; Scarisbrick JJ
Br J Dermatol; 2009 Jun; 160(6):1299-307. PubMed ID: 19222457
[TBL] [Abstract][Full Text] [Related]
4. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma.
McGinnis KS; Shapiro M; Vittorio CC; Rook AH; Junkins-Hopkins JM
Arch Dermatol; 2003 Jun; 139(6):771-5. PubMed ID: 12810509
[TBL] [Abstract][Full Text] [Related]
5. Acute hyperkeratotic and desquamative reaction in a patient with Sézary syndrome treated with bexarotene.
Bagazgoitia L; Pérez-Carmona L; Ríos L; Muñoz E; Harto A; Jaén P
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):389-90. PubMed ID: 18269619
[No Abstract] [Full Text] [Related]
6. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
7. Development of Hodgkin's lymphoma under bexarotene treatment for Sézary syndrome and review of the literature.
Sanli H; Akay BN; Ozcan M
J Drugs Dermatol; 2010 Aug; 9(8):1014-6. PubMed ID: 20684154
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.
Duvic M; Martin AG; Kim Y; Olsen E; Wood GS; Crowley CA; Yocum RC;
Arch Dermatol; 2001 May; 137(5):581-93. PubMed ID: 11346336
[TBL] [Abstract][Full Text] [Related]
9. Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine.
Richardson SK; Newton SB; Bach TL; Budgin JB; Benoit BM; Lin JH; Yoon JS; Wysocka M; Abrams CS; Rook AH
Am J Hematol; 2007 Sep; 82(9):792-7. PubMed ID: 17546636
[TBL] [Abstract][Full Text] [Related]
10. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
11. About the cutaneous targets of bexarotene in CTCL patients.
Knol AC; Quéreux G; Brocard A; Ballanger F; Khammari A; Nguyen JM; Dréno B
Exp Dermatol; 2010 Aug; 19(8):e299-301. PubMed ID: 19845753
[TBL] [Abstract][Full Text] [Related]
12. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
13. Biological effects of bexarotene in cutaneous T-cell lymphoma.
Budgin JB; Richardson SK; Newton SB; Wysocka M; Zaki MH; Benoit B; Rook AH
Arch Dermatol; 2005 Mar; 141(3):315-21. PubMed ID: 15781672
[TBL] [Abstract][Full Text] [Related]
14. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
15. Bexarotene monotherapy for patients with refractory Sézary syndrome.
Staib G; Scharffetter-Kochanek K
Dermatol Clin; 2008 Jan; 26 Suppl 1():61-3. PubMed ID: 18405190
[No Abstract] [Full Text] [Related]
16. Bexarotene combination therapy for patients with Sézary syndrome.
Ranki A
Dermatol Clin; 2008 Jan; 26 Suppl 1():55-7. PubMed ID: 18405189
[No Abstract] [Full Text] [Related]
17. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome.
Tsirigotis P; Pappa V; Papageorgiou S; Kapsimali V; Giannopoulou V; Kaitsa I; Girkas K; Papageorgiou E; Stavrianeas N; Economopoulos T; Dervenoulas J
Br J Dermatol; 2007 Jun; 156(6):1379-81. PubMed ID: 17459033
[No Abstract] [Full Text] [Related]
18. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Assaf C; Bagot M; Dummer R; Duvic M; Gniadecki R; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Sézary syndrome with bexarotene after IFNalpha and methotrexate failure.
Bagot M
Dermatol Clin; 2008 Jan; 26 Suppl 1():27-9. PubMed ID: 18405184
[No Abstract] [Full Text] [Related]
20. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Stern DK; Lebwohl M
J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
